NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...

NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Biohaven (NYSE:BHVN – Free Report) had its price objective lowered by Morgan Stanley from $69.00 to $63.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Highlights,Institutional firms have modified their holdings in Biohaven Ltd., contributing to shifts in stock ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed” data ...

Royal Bank of Canada restated their outperform rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report published ...

Three of VB's underlying holdings with notable upside to their analyst target prices are CG Oncology Inc (Symbol: CGON), Denali Therapeutics Inc (Symbol: DNLI), and Biohaven Ltd (Symbol ...